strategies such as small molecular compound development. In this work, a series of SARS-CoV-2 main protease (Mpro) inhibitors were designed and tested based on the active compound from high-throughput diverse compound library screens. The most efficacious compound (16b-3) displayed potent SARS-CoV-2 Mpro inhibition with an IC50 value of 116 nM and selectivity against SARS-CoV-2 Mpro when compared to
COVID-19 大流行严重影响了全球经济和公共卫生。尽管疫苗开发取得了成功,但它不足以对抗包括 Delta 变体在内的更具传染性的突变株,这表明需要替代治疗策略,例如
小分子化合物开发。在这项工作中,基于来自高通量不同化合物库筛选的活性化合物,设计并测试了一系列
SARS-CoV-2 主要
蛋白酶 (M pro )
抑制剂。与 PL pro相比,最有效的化合物 ( 16b-3)显示出有效的
SARS-CoV-2 M pro抑制作用,IC 50值为 116 nM 并且对
SARS-CoV-2 M pro具有选择性和 RdRp。这类新化合物可用作进一步优化抗 COVID-19 药物发现的潜在线索。